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Summary Tumour necrosis factor (TNF)-a induces apoptosis in a human acute myeloid leukaemia cell line,
Kasumi-l. To examine the role ofprotein phosphorylation in signal transduction of TNF-a-induced apoptosis,
a variant cell line resistant to TNF-a was established by an intermittent challenge of Kasumi-l cells with
increasing concentrations of TNF-a for 6 months. The mechanism of resistance to TNF-a appears to be in the
post-receptor pathway because expression of p55 TNF receptor in the variant cells is increased compared with
that of the parental Kasumi-I cells. In renaturation assays, TNF-a induced a rapid activation of different
protein kinases of different molecular weights, including the 50 kDa protein kinase (PK50) followed by the
35 kDa protein kinase (PK35), in the parental Kasumi-I cells. The dose-response of TNF-a required to
activate PK50 and PK35 was closely related to concentrations of TNF-a that induced apoptosis. Treatment of
Kasumi-1 cells with ceramide also activated PK35. In TNF-resistant variant cells, activation of PK35 in
response to TNF-a or ceramide was practically nil. These findings suggest that activation of PK35 through the
ceramide pathway may play an important role in signal transduction of TNF-a in the Kasumi-I cell line, while
the decreased activation of PK35 may explain the insensitivity of the variant cells towards TNF-a.
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Tumour necrosis factor (TNF)-a exerts multiple biological
activities in various cell systems, including inhibition of cell
growth, cytocidal activity and modulation of gene transcrip-
tion (Old, 1985; Beutler and Cerami, 1989; Vilcek and Lee,
1991). Two distinct TNF receptors of 75 kDa (P75 receptor)
(Smith et al., 1990) and 55 kDa (P55 receptor) (Loetscher et
al., 1990; Schall et al., 1990) have been identified. The P55
receptor was found to transmit cytotoxic effects of TNF
(Tartaglia et al., 1993). The 45 amino acids of the
intracellular domain of the P55 receptor (332-376) have
51% homology to the corresponding domain of the human
Fas antigen (230-274) (Itoh et al., 1991). Mutant proteins of
the P55 TNF receptor in which most of the intracellular
domain has been removed are defective in initiating
cytotoxicity, hence the importance of this domain in
mediating TNF signalling (Tartaglia et al., 1993). The
intracellular domain of the P55 receptor and that of the
P75 receptor do not have a kinase domain (Loetscher et al.,
1990; Schall et al., 1990), and little is known of the molecular
mechanism responsible for the multiple biological activities of
TNF.
A novel signal transduction pathway involved in mediating
some effects of TNF has been identified (Kim et al., 1991;
Kolesnick and Golde, 1994). This pathway, referred to as the
sphingomyelinase pathway, is initiated by activation ofneutral
sphingomyelinase, which hydrolyses membrane sphingomyelin
to ceramide. Ceramide acts as asecond messengermolecule and
can stimulate a membrane-bound serine/threonine kinase,
termed 97 kDa ceramide-activated protein kinase (Liu et al.,
1994). However, precise mechanisms leading to activation of
sphingomyelinase and downstream events after ceramide-
activated protein kinase remain unclear.
We report here that the human myeloid leukaemia cell
line, Kasumi-l (Asou et al., 1991), is sensitive to TNF-a-
induced apoptosis. Various protein kinases are activated in
the apoptotic process. Among these protein kinases, we
identified a rapid activation by TNF-o of the 50 kDa protein
kinase (PK50) followed by activation of the 35 kDa protein
kinase (PK35). However, TNF-a failed to activate PK35 in
the TNF-resistant variant cells selected from Kasumi-1 cells.
These findings suggest that PK50 and PK35 play important
roles in the signal transduction of TNF-a-induced apoptosis
in the human myeloid leukaemia cell line, Kasumi-1.
Materials and methods
Reagents
[y-32P]ATP (3000 Ci mmol-h) was purchased from ICN
Biomedicals (Costa Mesa, CA, USA). 4-[3-(4-Iodophenyl)-
2-(4-nitrophenyl) -2H -5-tetrazolio]-1,3 -benzene disulpho-
nate (WST-1) and 1-methoxy-5-methylphenazinium methyl-
sulphate (1-methoxy PMS) were purchased from Dojindo
(Kumamoto, Japan). Myelin basic protein (MBP), 0-
phosphoserine, O-phosphothreonine, O-phosphotyrosine,
ceramide and ATP were purchased from Sigma (St Louis,
MO, USA). Human TNF-a and monoclonal antibodies
against P55 and P75 TNF receptors were purchased from
Genzyme (Cambridge, MA, USA). Granulocyte macrophage
colony-stimulating factor (GM-CSF) was a gift from Sandoz.
Monoclonal anti-mitogen-activated protein (MAP) kinase
was purchased from Zymed (San Francisco, CA, USA).
Sepharose-conjugated goat anti-mouse IgG was purchased
from Organon Teknika (West Chester, PA, USA).
Selection of TNF-a-resistant Kasumi-J cells
Kasumi-1, a human acute myeloid leukaemia cell line (Asou
et al., 1991), has a characteristic chromosomal abnormality
including t(8;21). Cells were maintained at a density of 3 x 105
to 2 x 106 cells ml-' in a humidified atomosphere of 5%
carbon dioxide and 95% air in RPMI-1640 medium
supplemented with 10% (v/v) fetal bovine serum. TNF-a
(1 U ml-') was added to the culture of 3 x 107 Kasumi-1 cells
and incubated for 1 week. When cell viability decreased to
< 5%, cells were resuspended in medium without TNF-a and
allowed to grow for several days before TNF-a was re-added.
Intermittent exposure to increasing concentrations of TNF-a
was maintained for 6 months until cultures could be kept in
1000 U ml-' TNF-a. When TNF-a was removed from the
selective medium for as long as 6 months, re-exposure to
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September 1995TNF-oe did not lead to cell death. The TNF-resistant Kasumi-
1 cell line still possessed t(8;21) chromosomal abnormality
(data not shown).
Assessment of cell growth
The growth-inhibitory effects were assessed by plating cells in
96-multiwell dishes (Nunc 167008) at a final density of 5-
7 x 105 cells ml-'. Cells were incubated with or without
various concentrations ofTNF-cx for indicated times, then the
proliferation was measured by incubating cells with 0.5 mM
WST-l and 0.02 mM 1-methoxy PMS for 2 h, and the
absorbance was measured at 605 nm, as described (Ishiyama
et al., 1993).
Analysis of the expression of TNF receptor
Parental and variant Kasumi-I cells were analysed for
expressions of P55 and P75 TNF receptors by indirect
immunofluorescence with monoclonal antibodies against P55
and P75 TNF receptors. Fluorescence was evaluated on
FACScan flow cytometer, as described previously (Washio et
al., 1992).
Preparation of cell extract
Cells at logarithmic growth phase were incubated with or
without various concentrations of TNF-a at 37°C for
indicated times, and washed once with ice-cold phosphate-
buffered saline (PBS). All subsequent steps were carried out
at 4°C. The cells were resuspended in lysis buffer (20 mM
Tris-HCl, pH 7.5, 5 mM EGTA, 50 mM 2-glycerophosphate,
6 mM dithiothreitol, 0.5% Triton X-100, 0.1 mm sodium
fluoride, 1 mM sodium vanadate, 1 ,ug ml-' leupeptin, 2 mM
phenylmethylsulphonyl fluoride) to a concentration of
2.5 x 107 cells ml-' for 30 min and then centrifuged at
4000 g for 10 min. The supernatant served as the cell
extract. Protein concentration was determined using the
Bio-Rad protein assay system (Tokyo, Japan).
In vitro renaturation assay ofprotein kinase using
polyacrylamide gels containing MBP
Cell lysates were prepared as described above and were used
as the enzyme solution. Various kinase activities were
examined in gel renaturation assays essentially as described
by Kameshita and Fujisawa (1989), with a minor modifica-
tion. MBP (0.5 mg ml-') was added to the separating gel
solution just before polymerisation, as a substrate protein.
After electrophoresis, the gel was washed twice with 50 mM
Tris-HCl (pH 8.0), 20% 2-propanol to remove sodium
dodecyl sulphate (SDS) and twice with buffer A (50 mM
Tris-HCl (pH 8.0), 5 mM 2-mercaptoethanol), each wash for
30 min at room temperature. To denature proteins the gel
was treated twice with 6 M guanidine in buffer A with each
treatment for 30 min at room temperature. Enzymes in the
guanidine-treated gel were allowed to renature in 0.04%
Tween 40 in buffer A at 4°C for 16 h with several changes of
solution. After renaturation, the gel was preincubated in
buffer B (40 mM Tris-HCl (pH 8.0), 50 mm sodium chloride,
20 mm potassium chloride, 10 mm magnesium chloride,
0.1 mM EGTA, and 2 mM dithiothreitol) for 30 min at
room temperature. Phosphorylation was carried out by
incubating the gel with buffer B containing 20,M
[y-32P]ATP (10 4uCi ml-') for 60 min at 25°C. After incuba-
tion, the gel was washed thoroughly with 5% trichloroacetic
acid and 1% sodium pyrophosphate, dried, then either
processed for autoradiography or analysed using a Fujix
BAS2000 Bio-imaging analyser.
Phosphoamino acid analysis
Bands corresponding to PK50 and PK35 were excised from
dried gel after renaturation assay as described (Cooper et al.,
1983). The protein in the gel slice was digested with N-
TNF-cx activates multple serine/threonine protein kinases
M Ido et a!
361
tosylphenylalanyl chloromethyl ketone-treated type XIII
trypsin (1 mg ml-') and hydrolysed in 6 N hydrochloric
acid at 110°C for 1 h. The samples were lyophilised,
dissolved in water and electrophoresed on cellulose thin-
layer plate (Merck 5715) at pH 3.5 (5% acetic acid, 0.5%
pyridine) at 500 V for 60 min in the presence of authentic
standards of phosphoserine, phosphothreonine and phospho-
tyrosine. Standards were detected by ninhydrin staining and
radiolabelled amino acids were detected by autoradiography.
Immunoprecipitation of MAP kinase
The parental and the variant Kasumi-1 cells (5 x 106 cells)
were treated with either TNF-a (1000 U ml-') or GM-CSF
(1000 U ml-') for 15 min and washed with ice-cold PBS.
Immunoprecipitation of MAP kinase was done as described
by Gotoh et al. (1991). Immune complexes were then
collected on anti-mouse IgG-conjugated Sepharose beads
for 60 min, washed four times with lysis buffer and eluted
with SDS-PAGE sample buffer. Immunoprecipitated pro-
teins were either analysed with Western blotting using anti-
MAP kinase or in vitro renaturation kinase assay using MBP
as a substrate protein, as described above.
Results
Cell growth
The effects of TNF-a on the proliferation of parental and
variant Kasumi-1 cells were examined. As shown in Figure 1,
TNF-ac dose-dependently inhibited thegrowth ofparentalcells,
whereas the variant cells were completely resistant to TNF-a at
concentrations as high as 1000 U ml-'. There was a significant
difference in the sensitivity of these cell lines to TNF-a over
1 U ml-l at P<0.05. Cytological studies under light micro-
scopy revealed that TNF-a-treated parental cells exhibited
morphological features consistent with apoptosis, including
marked condensation and fragmentation of nuclei, whereas
untreated parental cells and both treated and untreated variant
cells rarely exhibited apoptosis (data not shown).
Expression of P55 and P75 TNF receptors
To determine the molecular mechanism of resistance to TNF-
a in variant cells, the expression of P55 and P75 TNF
receptors in both cell lines was examined. Figure 2 shows that
the expression of P55 TNF receptor in the variant cells was
m
0
C
a.)
4-i
0 0.)
0
0)
0 10 100 1000
TNF (U ml-1)
Figure 1 Effects of TNF-a on growth of parental (C]) and
variant (0) Kasumi-l cells. Cells (5-7 x 104/well) were incubated
with various concentrations of TNF-a for 48h, the proliferation
of the cells was measured by incubating cells with 0.5mm WST-1
and 0.02mm 1-methoxy PMS for 2h, then the absorbance at
605 nm was measured.
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Figure 2 Expression of P55 and
FACScan flow cytometer.
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Figure 3 Time course ofprotein kinase activation by TNF-a or ceramide. Parental and variant Kasumi-1 cells were treated without
or with TNF-a (lOOOUml- ) or ceramide (1OpM) at 37°C. Aliquots of 5 x 106 cells were collected before and 5, 10, 30 and 60min
after stimulation of cells with TNF-a or ceramide. The in vitro kinase assay was done using myelin basic protein as an in vitro
substrate as described in Materials and methods.
increased over that of the parental cells. Although the
expression of P75 TNF receptor in the parental cells was
not detectable, P75 TNF receptor was expressed in the
variant cells. Since the cytocidal effect of TNF-a was reported
to be transmitted through the P55 TNF receptor (Tartaglia et
al., 1993), the mechanism of resistance to TNF-a in the
variant cells would probably reside in signal transduction
pathways downstream of the P55 TNF receptor.
362 TNF-resistant
100,
. 9 ,' -AA iU 10o 10'Z l° 10"
o
Q
CL 0-
o
Q
U). 0
0)
LA
0-
100
50
0
101 102 103 104
* PK50
* PK35
5C
c
. f%d%
10°
madtA"-ftle- - aw-w"o-ITNF-a activates multiple serine/threonine protein kinases
M Ido et a!
In vitro renaturation assay for detection ofprotein kinases
To examine the possible role of protein kinases in the signal
transduction of TNF-oa, in vitro renaturation kinase assays
were done. As shown in Figure 3, eight protein kinases of
150 kDa, 120 kDa, 85 kDa, 65 kDa, 50 kDa, 42 kDa,
40 kDa and 35 kDa were detected in cell extract from
unstimulated parental Kasumi-1 cells. Stimulation of
parental cells with 1000 U ml-' TNF-a resulted in enhance-
ment of the activation of PK50 and PK35, with different
kinetics (Figure 3). The activation of PK50 was rapid after
stimulation with TNF-ax, hence this kinase probably locates
just downstream of the TNF receptor. PK35 was activated
between 30 and 60 min after stimulation of parental cells
with TNF-ax. Treatment of parental cells with ceramide
resulted in activation of PK35 but not in that of PK50. Since
the basal level of PK50 in the variant cell was twice as high
as that in the parental cells, the level of stimulation of PK50
in response to TNF-x was almost nil. Activation of PK35 in
response to TNF-a or ceramide was absent in the variant
cells. Phosphoamino acid analysis of PK50 and PK35
revealed them to be phosphorylated on serine and
threonine. (Figure 4).
The dose dependency of TNF-x for the activation ofPK50
and PK35 seems to be closely related to that for the
induction of growth inhibition in the parental cells (Figures 1
and 5). To determine the statistical validity of these data, we
performed several additional experiments and analysed the
data obtained with Student's t-test. Since the absolute
radioactivity of PK35 and PK50 varies from one experiment
to another, we evaluated the relative increase in these kinase
activities by dividing the radioactivity of PK35 and PK50 at
60 min after TNF-a stimulation with those at 0 min
respectively. As shown in Table I, TNF-a induced an
increase in PK35 and PK50 activity in the parental
Kasumi- 1 cell line. However, no increase in these kinase
activities could be seen in the TNF-resistant cell line. There is
a significant difference in the activation of these kinase levels
between the parental and the TNF-resistant cell lines.
From their similarity in molecular weight and their ability
to phosphorylate MBP, it was suspected that one of these
kinases (PK50 or PK35) would be MAP kinase. To address
this question, cell extracts from parental and variant cells,
treated with or without TNF-ax or GM-CSF for 15 min, were
evaluated for MAP kinase by immunoprecipitation with anti-
MAP kinase and renaturation kinase assay. As shown in
Figure 6, TNF-a did not activate MAP kinase even in the
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Figure 5 Concentration dependency of TNF-a for activation of
protein kinases using a myelin basic protein as an in vitro
substrate. Parental and variant Kasumi-1 cells were treated with
various concentrations of TNF-a at 37°C for 60min, then extracts
were prepared and subjected to in vitro kinase assay as described
in Materials and methods. Lanes 1-5, treatment of cells with 0,
1, 10, 100 and 100OUml-1 of TNF-a respectively.
Table I The effect of TNF-a on the activation of PK35 and PK50
PK35a PK5Oa
Parental 11.4±7.31 (n=8) 2.67 ± 1.26 (n =6)
TNF-resistant 1.21 ± 0.67 (n = 5) 1.12 ± 0.32 (n = 5)
P-valueb <0.0056 < 0.029
aRelative increase in protein kinase activities was calculated as
follows: (PSL-BG) at 60 min/(PSL-BG) at 0 min. bStudent's t-test. The
statistical analysis ofPK35 and PK50 activation after stimulation with
TNF-a. Parental and variant Kasumi-l cells were treated without or
with TNF-a (1000 U ml-1) at 37°C for 60 min. Aliquots of5 x 106 cells
were collected and the in vitro kinase assay was performed as described
in Materials and methods. Protein kinase activities were analysed with
Bio-imaging analyser and are expressed as (PSL-BG) indicating
ghotostimulated luminescence value minus background value. The
2pincorporation into myelin basic protein corresponding to PK35 and
PK50 at 0 and 60 min after TNF stimulation was measured. The values
at 60 min were divided by those at 0 min. These values, named as the
relative increase in protein kinase activities, were statistically analysed
with Student's t-test between parental and TNF-resistant Kasumi-I
cells.
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Figure 4 Identification of phosphoamino acid in myelin basic
protein by PK50 and PK35. Phosphoamino acid analysis was
made as described in Materials and methods. PS, PT and PY
indicate phosphoserine, phosphothreonine and phosphotyrosine
respectively.
parental Kasumi-l cells, whereas GM-CSF activated MAP
kinase in both cell lines. Thus, TNF-a-activated kinases,
including PK50 and PK35, are different from MAP kinase.
Discussion
The human acute myeloid leukaemia cell line, Kasumi-1, is
very sensitive to TNF-oa-induced cell death (IC50=4.33 U
ml- ). Light microscopy and DNA fragmentation studies
revealed that TNF-a induces cell death through apoptosis
rather than through necrosis (data not shown). To better
understand the molecular mechanisms of TNF-ac on Kasumi-
1 cells, we selected variant cells resistant to TNF-a by
intermittent challenge of TNF-c for 6 months. Even when
these cells were grown in the absence of TNF-a for more than
6 months, re-exposing them to TNF-a did not induce
apoptosis, even at concentrations as high as 1000 U ml-'.
We asked if the down-regulation of TNF receptor was
responsible for the insensitivity of the variant cells. We found
that the expression of both P55 and P75 TNF receptors is
increased, hence, mechanisms related to resistance of the
variant cells to TNF-ai are located downstream from the TNF
receptor.
Several serine/threonine kinases are apparently involved in
the signal transduction of TNF (Lint et al., 1992), including
31
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Figure 6 Activation of MAP kinase by TNF-a or GM-CSF. Cell lysates (2mg) from parental and variant cells treated without
(lane 1) or with 1000UmlF1 TNF-cx (lane 2) or 1000 Uml1 GM-CSF (lane 3) for 15mi were incubated with monoclonal anti-
MAP kinase and precipitated with anti-mouse IgG-conjugated Sepharose. Immunoprecipitated proteins were analysed by in vitro
kinase assay or Western blotting. HC, LC, and MAPK indicate the heavy chain, the light chain ofprecipitated immunoglobulin and
MAP kinase respectively.
protein kinase C, MAP kinase (Vietor et al., 1993), S6 kinase,
casein kinase II and stress-activated protein kinase (SAPK)
(Kyriakis et al., 1994). In the present study, we examined the
effect of TNF-a on activation of protein kinases, using
renaturation assays. In the parental Kasumi-1 cells, TNF-a
stimulated serine/threonine kinases including PK50 and
PK35, which are different from MAP kinase. SAPK is a
proline-directed serine/threonine kinase and belongs to the
family of MAP kinase. SAPK was found to be activated by
stressful stimuli including treatment of cells with TNF,
cytotoxic drugs or heat shock (Kyriakis et al., 1994).
Although PK50 and PK35 were not identified, the similarity
in molecular weight and the ability of these kinases to
phosphorylate MBP suggest that one of them may be related
to SAPK and further studies to determine this are ongoing.
Some TNF actions are considered to be transmitted
through the activation of sphingomyelinase and the
subsequent generation of ceramide (Kolesnick and Golde,
1994). We also examined the effect ofceramide on the growth
and the activation of these kinases. Treatment of parental
Kasumi-1 cells with ceramide resulted in growth inhibition
(data not shown) and in activation of PK35 (Figure 3).
However, PK50 could not be activated by ceramide.
Therefore, PK50 is either upstream of sphingomyelinase or
resides in a different signalling pathway. The variant cells
showed resistance to the growth-inhibitory effect of ceramide
(data not shown). In addition, PK35 could not be activated
when the variant cells were treated with TNF-oa or ceramide.
Therefore, TNF-a may transmit signals through the
sphingomyelinase pathway and may induce PK35 activa-
tion, which would result in an apoptosis in Kasumi-I cells.
Ceramide is reported to activate 97 kDa serine/threonine
kinase, termed ceramide-activated protein kinase (Kolesnick
and Golde, 1994). In the present study, we found that
treatment of parental cells with TNF-a or ceramide resulted
in activation of PK35 (Figure 3). PK35 and ceramide-
activated protein kinase can use MBP as an in vitro substrate.
Liu et al. (1994) reported that treatment of HL-60 cells with
TNF resulted in activation of ceramide-activated protein
kinase between 5 and 10 min. In the present study, we noted
that PK35 is activated around 60 min after TNF treatment.
Hence, in size and kinetics of activation, PK35 may differ
from ceramide-activated protein kinase.
In conclusion, TNF-a stimulates several serine/threonine
kinases including PK50 and PK35 in parental Kasumi-1 cells.
PK35 may prove to be a new member of the ceramide-
activated protein kinase family and the lack of the activation
of PK35 may be related to insensitivity of the variant cells to
TNF-cc.
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